OTCMKTS:CLXPF Cybin (CLXPF) Stock Price, News & Analysis → This AI Trade Machine Made 1,729%* (With 89% Wins) (From Prosper Trading Academy) (Ad) Free CLXPF Stock Alerts $0.35 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.34▼$0.3550-Day Range$0.32▼$0.4652-Week Range$0.49▼$3.38Volume2.19 million shsAverage Volume551,962 shsMarket Capitalization$52.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Cybin alerts: Email Address Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Cybin Stock (OTCMKTS:CLXPF)Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.Read More CLXPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLXPF Stock News HeadlinesSeptember 14, 2023 | finance.yahoo.comCybin Inc protects IP with granting of 2nd US Patent for its deuterated analog programsJanuary 16, 2023 | benzinga.comPsychedelics Companies Join The Race To Develop Much-Needed Anxiety TreatmentApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.October 6, 2022 | businesswire.comCybin Provides Update on its Intellectual Property Portfolio - Business WireOctober 4, 2022 | benzinga.comCybin, GH Research Among Top Psychedelic Movers Of Today - Numinus Wellness (OTC:NUMIF), Compass Pathways - BenzingaSeptember 29, 2022 | proactiveinvestors.comMindset Pharma says licensing agreement with Cybin gives it multiple 'shots for the goal' - Proactive Investors USASeptember 27, 2022 | benzinga.comCybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds FamilySeptember 27, 2022 | proactiveinvestors.comNA Proactive news snapshot: Nevada Copper, Mindset Pharma, EverGen Infrastructure, Psyched Wellness, BetterLife Pharma, Endexx, Group Eleven Resources... - Proactive Investors USAApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.September 21, 2022 | businesswire.comCybin to Participate in Upcoming Scientific and Investor Conferences - Business WireSeptember 21, 2022 | streetinsider.comCybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks 'Tremendous' Milestone as First Participants Receive Initial CYB003 Dose - StreetInsider.comSeptember 20, 2022 | businesswire.comCybin Achieves Research and Development Milestones Ahead of Projected Timelines - Business WireSeptember 9, 2022 | bloomberg.comFirst Africa Cannabis SPAC to Go Ahead With Cilo Cybin Listing - BloombergSeptember 7, 2022 | benzinga.comCOMP SERVICES (CMPS), (CSE:OPTI) – Psychedelics May Make People Less Afraid of Death - BenzingaSeptember 1, 2022 | nasdaq.com7 Psychedelics Stocks to Buy for a Big Drug Boom - NasdaqSeptember 1, 2022 | proactiveinvestors.comCybin makes positive progress towards its goal of advancing psychedelics to therapeutics - Proactive Investors USAAugust 31, 2022 | benzinga.com(ALID), ATA (ATAI), (BMNDF), COMP SERVICES (CMPS), Cybin Inc. Common Shares (CYBN), Small Pharma (DMTTF), - BenzingaAugust 31, 2022 | benzinga.comCybin Inc. Common Shares (CYBN) – Cybin Announces Final Adelia Milestone Achievement - BenzingaAugust 31, 2022 | businesswire.comCybin Announces Final Adelia Milestone Achievement - Business WireAugust 30, 2022 | finance.yahoo.comCybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder - Yahoo FinanceAugust 30, 2022 | businesswire.comWellbeing' CEO Joins Benzinga's Psychedelic Advisory Board - Business WireAugust 30, 2022 | streetinsider.comBioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD - StreetInsider.comAugust 30, 2022 | businesswire.comCybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder - Business WireAugust 26, 2022 | streetinsider.comCybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector - StreetInsider.comAugust 24, 2022 | proactiveinvestors.comStifel analysts still bullish on psychedelic stocks, citing attractive risk-reward profile - Proactive Investors USAAugust 17, 2022 | benzinga.comMDD - Latest News and breaking headlines - BenzingaAugust 17, 2022 | marketscreener.comCybin, Clinilabs Says DEA Grants it Schedule 1 License for CYB003 to Treat Major Depressive Disorder - Marketscreener.comSee More Headlines Receive CLXPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Holding & Other Investment Offices Sub-IndustryN/A Current SymbolOTCMKTS:CLXPF CUSIPN/A CIKN/A Webwww.cybin.com Phone416 567 4675FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio13.57 Quick Ratio13.57 Sales & Book Value Annual Sales$680,000.00 Price / Sales76.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book0.80Miscellaneous Outstanding Shares148,598,000Free FloatN/AMarket Cap$52.01 million OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Eric So L.L.B. (Age 45)LLB, Co-Founder, Pres & Exec. Chairman Mr. Douglas L. Drysdale (Age 51)Chief Exec. Officer Mr. Paul Glavine (Age 31)Co-Founder, Chief Growth Officer & Director Mr. John Kanakis (Age 40)Co-Founder & Chief Bus. Officer Mr. Greg Cavers (Age 50)Chief Financial Officer Dr. Alex L. Nivorozhkin Ph.D. (Age 61)Chief Scientific Officer Mr. Gabriel Fahel (Age 45)Chief Legal Officer Sara Brittany SomersetChief Communications OfficersLori ChallengerChief of StaffJames AndrewsChief Cultivation & Extraction OfficerMore ExecutivesKey CompetitorsPrenetics GlobalNASDAQ:PREFuture Health ESGNASDAQ:FHLTARYA Sciences Acquisition Corp IVNASDAQ:ARYDCERo TherapeuticsNASDAQ:CEROARCA biopharmaNASDAQ:ABIOView All Competitors CLXPF Stock Analysis - Frequently Asked Questions How have CLXPF shares performed in 2024? Cybin's stock was trading at $0.41 at the start of the year. Since then, CLXPF shares have decreased by 14.6% and is now trading at $0.35. View the best growth stocks for 2024 here. How do I buy shares of Cybin? Shares of CLXPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CLXPF) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
